All News

portfolio-news

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

Posted November 7, 2023

portfolio-news

Cumulus Neuroscience Presents Data at CTAD 2023 Annual Meeting

Posted October 25, 2023

portfolio-news

AviadoBio Announces Initiation of Phase 1/2 Clinical Trial, ASPIRE-FTD, Evaluating AVB-101 in People with Frontotemporal Dementia with GRN Mutations

Posted October 10, 2023

portfolio-news

Ion Channel Drug Developer Maxion Therapeutics Appoints Eva-Lotta Allan as Chair of its Board of Directors

Posted September 22, 2023

ventures-news

Ozlo Sleep Emerges from Stealth and Unveils Flagship Product Ozlo Sleepbuds®

Posted August 4, 2023

portfolio-news

Cumulus Neuroscience Presents Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Posted July 18, 2023

portfolio-news

Cumulus Neuroscience Announces Research Collaboration with the Universities of Bath and Bristol on Development of Breakthrough Test for Early Detection of Alzheimer’s Dementia

Posted July 13, 2023

portfolio-news

Cumulus Neuroscience Presents Key Data at the 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Posted July 12, 2023

ventures-news

LifeArc Ventures Invests in Affect Therapeutics $16 million Series A to Deliver Next Generation Addiction Recovery

Posted July 12, 2023

portfolio-news

Cumulus Neuroscience to Present Data at AAIC 2023 Annual Meeting and Technology and Dementia Preconference

Posted July 11, 2023

portfolio-news

Cumulus Neuroscience to Present Data at 2023 ENCALS Annual Meeting on Patients with Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD)

Posted July 7, 2023

portfolio-news

Cumulus Neuroscience Receives FDA 510(k) Clearance for Award-Winning,First-In-Class NeurophysiologyPlatform for At-Home Use

Posted June 1, 2023